HRP20220234T1 - Kristalni oblici - Google Patents

Kristalni oblici Download PDF

Info

Publication number
HRP20220234T1
HRP20220234T1 HRP20220234TT HRP20220234T HRP20220234T1 HR P20220234 T1 HRP20220234 T1 HR P20220234T1 HR P20220234T T HRP20220234T T HR P20220234TT HR P20220234 T HRP20220234 T HR P20220234T HR P20220234 T1 HRP20220234 T1 HR P20220234T1
Authority
HR
Croatia
Prior art keywords
4carbonyl
phosphono
pyrrolidin
propionyl
piperazine
Prior art date
Application number
HRP20220234TT
Other languages
English (en)
Croatian (hr)
Inventor
Daniel Leuenberger
Stefan Reber
Markus Von Raumer
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of HRP20220234T1 publication Critical patent/HRP20220234T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20220234TT 2016-09-22 2017-09-21 Kristalni oblici HRP20220234T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
EP17771436.7A EP3515924B1 (en) 2016-09-22 2017-09-21 Crystalline forms
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (1)

Publication Number Publication Date
HRP20220234T1 true HRP20220234T1 (hr) 2022-05-13

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220234TT HRP20220234T1 (hr) 2016-09-22 2017-09-21 Kristalni oblici

Country Status (27)

Country Link
US (4) US10730896B2 (https=)
EP (2) EP3981774A1 (https=)
JP (1) JP7097369B2 (https=)
KR (1) KR102552795B1 (https=)
CN (1) CN109715639B (https=)
AU (1) AU2017331930B2 (https=)
CA (1) CA3037794A1 (https=)
CL (1) CL2019000728A1 (https=)
CY (1) CY1125052T1 (https=)
DK (1) DK3515924T3 (https=)
EA (1) EA201990723A1 (https=)
ES (1) ES2908572T3 (https=)
HR (1) HRP20220234T1 (https=)
HU (1) HUE057772T2 (https=)
IL (1) IL265445B2 (https=)
LT (1) LT3515924T (https=)
MA (1) MA46266B1 (https=)
MX (1) MX381590B (https=)
MY (1) MY193080A (https=)
PH (1) PH12019500567B1 (https=)
PL (1) PL3515924T3 (https=)
PT (1) PT3515924T (https=)
RS (1) RS62946B1 (https=)
SI (1) SI3515924T1 (https=)
TW (1) TWI752086B (https=)
UA (1) UA124073C2 (https=)
WO (1) WO2018055016A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057772T2 (hu) 2016-09-22 2022-06-28 Idorsia Pharmaceuticals Ltd Kristályos formák
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
PT4181872T (pt) 2020-07-15 2026-01-22 Viatris Asia Pacific Pte Ltd Composição farmacêutica aquosa compreendendo um antagonista do recetor p2y12
JP2024524658A (ja) * 2021-07-13 2024-07-05 イドルシア・ファーマシューティカルズ・リミテッド 4-((r)-2-{[6-((s)-3-メトキシ-ピロリジン-1-イル)-2-フェニル-ピリミジン-4-カルボニル]-アミノ}-3-ホスホノ-プロピオニル)-ピペラジン-1-カルボン酸ブチルエステルの合成方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
DE60022508T2 (de) 1999-06-14 2006-06-08 Eli Lilly And Co., Indianapolis Inhibitoren von serin proteasen
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
OA12970A (en) 2002-12-11 2006-10-13 Schering Ag 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists.
CA2521313A1 (en) 2003-04-09 2004-10-28 Wyeth Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.o)non-1(7)-3n-2-yl)-al kyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
WO2007046075A1 (en) 2005-10-21 2007-04-26 Actelion Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
KR20100015886A (ko) 2007-04-23 2010-02-12 사노피-아벤티스 P2y12 길항제로서의 퀴놀린-카복스아미드 유도체
ES2388958T3 (es) 2007-11-29 2012-10-22 Actelion Pharmaceuticals Ltd. Derivados de acido fosfonico y su uso como antagonista del receptor P2Y12
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
WO2009080227A2 (en) 2007-12-26 2009-07-02 Sanofi-Aventis Pyrazole-carboxamide derivatives as p2y12 antagonists
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
KR101694563B1 (ko) 2009-04-08 2017-01-09 액테리온 파마슈티칼 리미티드 Adp 수용체 길항제로서 6-(3-아자-비시클로〔3.1.0〕헥스-3-일)-2-페닐-피리미딘
EP2421859B1 (en) 2009-04-22 2014-04-09 Actelion Pharmaceuticals Ltd. Thiazole derivatives and their use as p2y12 receptor antagonists
HUE057772T2 (hu) 2016-09-22 2022-06-28 Idorsia Pharmaceuticals Ltd Kristályos formák
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
PT4181872T (pt) 2020-07-15 2026-01-22 Viatris Asia Pacific Pte Ltd Composição farmacêutica aquosa compreendendo um antagonista do recetor p2y12

Also Published As

Publication number Publication date
IL265445B1 (en) 2024-01-01
IL265445B2 (en) 2024-05-01
US12227532B2 (en) 2025-02-18
US11365209B2 (en) 2022-06-21
TWI752086B (zh) 2022-01-11
EP3981774A1 (en) 2022-04-13
EP3515924A1 (en) 2019-07-31
US10730896B2 (en) 2020-08-04
TW201813965A (zh) 2018-04-16
KR20190052704A (ko) 2019-05-16
MY193080A (en) 2022-09-26
EA201990723A1 (ru) 2019-10-31
LT3515924T (lt) 2022-03-10
CY1125052T1 (el) 2024-02-16
JP2019529553A (ja) 2019-10-17
NZ750772A (en) 2023-10-27
CN109715639A (zh) 2019-05-03
IL265445A (en) 2019-05-30
MX381590B (es) 2025-03-12
US20220275011A1 (en) 2022-09-01
PT3515924T (pt) 2022-03-11
KR102552795B1 (ko) 2023-07-06
MA46266A (fr) 2019-07-31
MA46266B1 (fr) 2022-02-28
UA124073C2 (uk) 2021-07-14
US20200017534A1 (en) 2020-01-16
PH12019500567A1 (en) 2019-11-18
CL2019000728A1 (es) 2019-07-05
AU2017331930A1 (en) 2019-03-07
ES2908572T3 (es) 2022-05-03
CA3037794A1 (en) 2018-03-29
US20210009614A1 (en) 2021-01-14
EP3515924B1 (en) 2021-12-15
HUE057772T2 (hu) 2022-06-28
US20250163086A1 (en) 2025-05-22
BR112019004845A2 (pt) 2019-06-04
PL3515924T3 (pl) 2022-04-11
JP7097369B2 (ja) 2022-07-07
PH12019500567B1 (en) 2024-01-31
CN109715639B (zh) 2022-04-19
RS62946B1 (sr) 2022-03-31
AU2017331930B2 (en) 2021-07-15
SI3515924T1 (sl) 2022-04-29
DK3515924T3 (da) 2022-03-21
WO2018055016A1 (en) 2018-03-29
MX2019003093A (es) 2019-07-18

Similar Documents

Publication Publication Date Title
AR128483A2 (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos
HRP20220234T1 (hr) Kristalni oblici
HRP20160813T1 (hr) Natrijeve i kalcijeve soli derivata dihidrokinazolina i njihova upotreba kao antivirusna sredstva
HRP20210675T1 (hr) Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa
BRPI0407149A8 (pt) formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais
JP2018520205A5 (https=)
HRP20201343T1 (hr) Kristalni oblici 5-kloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidin-2,4-diamina
FI4293009T3 (fi) Fenfluramiinikoostumukset ja menetelmät niiden valmistamiseksi
HRP20241280T1 (hr) Kruti oblici rukapariba i soli rukapariba
HRP20160886T1 (hr) Besilatna i tosilatna sol derivata dihidrokinazolina i njihova upotreba kao protuvirusna sredstva
EA201990688A1 (ru) Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение
EP4327880A3 (en) Solid state form of ribociclib succinate
HRP20210551T1 (hr) Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za liječenje shizofrenije
EA200901146A1 (ru) Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли
WO2015011120A3 (en) Salts of dasatinib in crystalline form
HRP20201470T1 (hr) Oblici soli nilotiniba u krutom stanju
JP2019529553A5 (https=)
HRP20250660T1 (hr) Čvrsti oblici ixazomib citrata
JP2018502165A5 (https=)
MX381611B (es) Derivados de c-glicósido que tienen anillos de fenilo condensado o sales farmacéuticamente aceptables de los mismos, método para prepararlos y composición farmacéutica que los contiene.
HRP20211524T1 (hr) Sol derivata cefalosporina, kristalni kruti oblik istog i postupak za njegovu proizvodnju
MX358669B (es) Croman-6-iloxi-cicloalcanos sustituidos y su uso como productos farmaceuticos.
RU2017131286A (ru) Новые полиморфные формы миноциклинового основания и способы их получения
HRP20251324T1 (hr) Oblici soli rukapariba u krutom stanju
HRP20231538T1 (hr) Farmaceutski spoj, postupak za njegovu izradu i uporaba kao lijekovitog sredstva